#4740 DIFFERENT ORAL IRON PREPARATIONS IN CHRONIC KIDNEY DISEASE: A COMPARATIVE ANALYSIS

Abstract

Abstract Background and Aims Anaemia is common and undertreated morbidity in chronic kidney disease (CKD). Optimal approach to treatment of renal anemia is matter of ongoing debate. This is the first comparative analysis between different oral iron preparations in CKD patients. Method This prospective observational multicentre study was performed from March 2019 to May 2021. In total, 214 non-dialysis dependent CKD stage3-5 patients with 3 months follow-up were included. Inclusion & exclusion criteria are mentioned in Table 1. Primary outcome was rise in Haemoglobin at 1 month/3 months & rise in Transferrin saturation (TSAT) at 3 months. Treatment adherence was also evaluated. Figure 1 depicts the study model. Results Table 2 depicts demographic data while Table 3 depicts correlation between baseline haemoglobin & different modifiable/non-modifiable variables. Rise in haemoglobin & TSAT with different oral iron preparations has been shown in Table 4 while the ANOVA tables for clinical significance of this rise has been shown in Figures 2 & 3. Rise in haemoglobin and TSAT% was highest with Ferric Pyrophosphate > Ferric Fumarate > Ferric Saccharate. Treatment adherence was highest with Ferric Pyrophosphate (100%) > Heme Iron Polypeptide (91.4%) > Ferrous Ascorbate (88.9%). Conclusion Ferric Pyrophosphate is most effective among available oral iron preparations in rising haemoglobin level. It effectively repletes iron stores & has highest treatment adherence.